Central Nervous System Therapeutics Market Snapshot
“The Central Nervous System Therapeutics Market is estimated to increase at a CAGR 6.13% from $ 126.25 Billion in 2023 to $ 203.25 Billion by 2030.”
Central Nervous System pharma companies are focusing on introducing new medications to meet the increasing global demand for CNS treatments, driven by the increasing frequency of neurodegenerative illnesses and the need to broaden their product line.
The increasing prevalence of neurological illnesses and the growing need for brain therapies are driving the growth of central nervous system (CNS) treatments.
The market potential for these treatments is expected to be influenced by factors such as increased research activity in CNS neuroscience, rising healthcare expenditures, and the increasing prevalence of CNS disorders.
The use of CNS treatments is influenced by factors such as increasing public stress, knowledge of neurological illnesses, and lifestyle-related issues. Due to the complexity of CNS pharmaceuticals, high costs, and increasing side effects, regulatory authorities take longer to review and approve CNS treatments than non-CNS therapies.
Over the past few years, lifestyle changes have significantly impacted population health trends, leading to increased prevalence of diseases like CNS illnesses and Parkinson's and Alzheimer's disease. Poor lifestyle choices have also contributed to the rise in these diseases worldwide.
>>>Download Sample Report Now:https://marketreportservice.com/request-sample/central-nervous-system-therapeutics-market-54691
COVID-19 Impact
The COVID-19 pandemic significantly impacted the CNS therapies market globally, as lockdown limits did not cause many mental health issues. The WHO reported a 25% global increase in worry and melancholy during the first year, leading to disruptions to mental health services and increased prevalence of mental health issues, creating significant care gaps and negatively affecting the market.
The use of CNS therapies is increasing due to the increasing number of patients with CNS diseases, including mental health and neurodegenerative ones. The World Health Organisation reports that over 10 million new dementia cases occur annually, with Alzheimer's disease being the most prevalent type, accounting for 60-70% of all cases, and over 55 million individuals worldwide suffering from the disease.
Segment Analysis
The Parkinson's Disease segment is predicted to hold a significant market share in the degenerative disease segment over the forecast period.
A degenerative condition that affects the neurological system and the body components that are regulated by the nerves is Parkinson's disease. When nerve cells in the brain and peripheral nervous systems stop working and die, a degenerative illness results.
Due to rising rates of Parkinson's disease and ongoing research and development of new treatments for the condition, the Parkinson's disease segment is anticipated to hold a sizable market share over the course of the projection period.
In the United States, around 90,000 persons are diagnosed with Parkinson's disease (PD) annually, up 50% from the previous projection of 60,000 cases, according to a research released by the Parkinson's Foundation in December 2022.
Furthermore, according to the previously cited source, the quantity of individuals with Parkinson's.
The segment's growth is attributed to the increasing demand for pharmaceuticals and awareness of mental health issues, particularly CNS cancer, which is expected to experience a positive CAGR in the coming years, fueled by substantial investments in research and development.
Growth Drivers
The global demand for advanced therapies is fueled by the rise in the prevalence of central nervous system disorders, with the market expected to grow due to advancements in medications and diagnostics. The World Health Organization estimates that 1 billion people worldwide suffer from these disorders, prompting pharmaceutical companies to invest heavily in research for novel CNS medicines.
The patent expiration of generic medications like Invega and Copaxone has increased treatment rates in low- and middle-income economies. US FDA approved two generic versions of Copaxone. New therapies are entering the global CNS therapeutic market more easily due to increased spending in clinical trials and drug development. Government rules and bodies like the FDA and EMA monitor these outcomes.
Market Restraints
The central nervous system treatment requires significant investment in research and development, as it must pass through blood-brain barriers. The development and licensing process for such pharmaceuticals are longer, and the market faces challenges like patient acquisition and increased approval costs.
Opportunity
The market for CNS therapeutics is expanding due to the increasing number of people suffering from neurological illnesses, high diagnosis rates in developed and developing nations, and the introduction of new antipsychotic medications. The market is driven by innovative pharmaceuticals and strategic initiatives by major industry players.
The rise in neurological illnesses' incidence and prevalence, coupled with the ageing population and the increasing number of products being introduced to treat neurological illnesses, presents significant prospects for market expansion.
Challenges
The central nervous system therapeutic sector faces challenges due to government regulations, including an approval procedure for medications used to treat the central nervous system, which is further complicated by severe rules.
Competitive Landscape of the Central Nervous System Therapeutics Market Analysis
- Biogen Inc.
- Otsuka Pharmaceutical Co. Ltd
- Eli Lilly and Company
- Merck & Co.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
- Pfizer Inc.
- GlaxoSmithKline PLC
New Developments in Central Nervous System Therapeutics Market
MARCH 17, 2023- Biogen Inc. announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Stifel 2023 CNS Days. The webcast will be live on Tuesday, March 28, 2023, at 9:15 a.m. ET. To access the live webcast, please visit the Investors section of Biogen’s website at investors.biogen.com. An archived version of the webcast will be available for at least 90 days following the presentation.
11 OCT 2023- Merck, a leading science and technology company, today announced new five-year data from the open-label extension (OLE) of the Phase II clinical trial, which demonstrated that people with relapsing multiple sclerosis (RMS) treated with investigational BTK inhibitor (BTKi) evobrutinib continued to have low annualized relapse rates (ARR), with a high proportion of patients showing no evidence of clinical worsening. Additional patient-reported data from the study showed statistically significant and clinically meaningful improvements in mental health and vitality, which is closely related to fatigue. These data, presented at the 9th Joint ECTRIMS-ACTRIMS meeting, may indicate the long-term positive benefits of evobrutinib for people with RMS.
Regional Analysis of Global Central Nervous System Therapeutics Industry
North America
North America is expected to dominate the pharmaceutical market due to its advanced technology, increased research and development in the US and Canada, and the rise in central nervous system diseases.
The Alzheimer's Association predicts that 6.7 million Americans 65 and older will have Alzheimer's dementia by 2023, a figure expected to rise as the geriatric population in the region ages.
Leading companies and increased financial commitments to innovative treatments are significantly affecting the market expansion in this area. The market for therapies targeting the central nervous system has grown exponentially due to rising public awareness of mental health issues and robust pipeline medicines in North America.
Asia Pacific
The Asia Pacific market is expected to be the most advantageous in the coming years due to the increasing number of patients with unmet medical needs and government spending on healthcare infrastructure.
Non-profit organizations are raising awareness about mental health and CNS therapies, offering free treatments for central nervous system ailments, which is expected to propel the expansion of the market.
Segments Covered in the Central Nervous System Therapeutics Market Report
Segment by Disease
- Neurovascular Diseases
- Trauma
- Mental Health
- Degenerative Disease
- Infectious Diseases
- Cancer
- and Others
Segment Drug Class
- Analgesics
- Antidepressants
- Anesthetics
- Anti-Parkinson Drugs
- Anti-Epileptics
- and Other Drug Classes
Market by Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Frequently Asked Questions
What are some applications of Central Nervous System Therapeutics?
Central nervous system agents can be used as analgesics, anesthetics, anti-emetics, anti-convulsants, and have many other therapeutic uses.
What is the expected growth rate of the Central Nervous System Therapeutics market over the next 7 years?
Central Nervous System Therapeutics Market is estimated to increase at a CAGR 6.13% from $ 126.25 Billion in 2023 to $ 203.25 Billion by 2030.
Who are the major players in the Central Nervous System Therapeutics market and what is their market share?
Biogen Inc, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Pfizer Inc., and GSK plc, are prominent players operating and dominating in the market.
Who are the top 3 Central Nervous System Therapeutics Market Key Vendors?
Biogen Inc, Eli Lilly and Company, Novartis AG, are key players in the Central Nervous System Therapeutics market.
Which geographical areas dominate the worldwide market for Central Nervous System Therapeutics?
North America region are emerging as the top regional markets for Central Nervous System Therapeutics solutions.
1.SUMMARY
1.1. Central Nervous System Therapeutics Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of Central Nervous System Therapeutics
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Central Nervous System Therapeutics
3.7 Challenges associated with Central Nervous System Therapeutics
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 Central Nervous System Therapeutics: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. Central Nervous System Therapeutics: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. Central Nervous System Therapeutics: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Central Nervous System Therapeutics: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Central Nervous System Therapeutics
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- Biogen Inc.
- Otsuka Pharmaceutical Co. Ltd
- Eli Lilly and Company
- Merck & Co.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
- Pfizer Inc.
- GlaxoSmithKline PLC
